Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study

Ting Deng,1,* Lei Yan,2,* Jing Li,1 Guochen Liu,1 Aijun Yin,3 Yanling Feng,1 Min Zheng,1 Chuyao Zhang,1 He Huang,1 Qidan Huang,1 An Lin,4 Jie Jiang,3 Beihua Kong,3 Jihong Liu1,* 1Department of Gynecological Oncology, Sun Yat-Sen University Cancer Center, State Key...

Full description

Saved in:
Bibliographic Details
Main Authors: Deng T, Yan L, Li J, Liu G, Yin A, Feng Y, Zheng M, Zhang C, Huang H, Huang Q, Lin A, Jiang J, Kong B, Liu J
Format: Article
Language:English
Published: Dove Medical Press 2025-07-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Ovarian cancer
niraparib
anlotinib
long-term safety
multidisciplinary management
Online Access:https://www.dovepress.com/adverse-event-management-in-patients-with-platinum-resistant-ovarian-c-peer-reviewed-fulltext-article-TCRM
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/adverse-event-management-in-patients-with-platinum-resistant-ovarian-c-peer-reviewed-fulltext-article-TCRM

Similar Items